**SUPPLEMENTAL DATA**

**Table e-1. Significant lab values before/during/after COVID-19 infection**

Laboratory tests obtain before, during, and after COVID-19 infection are listed below. Cases were then separated by hospitalization status [non-hospitalized (left) and hospitalized (right)]. Laboratory values were then categorized as before, during, or after COVID-19 infection with the leftward column indicated average with standard error of the mean in parenthesis, and the rightward column indicating the number of values included in that average. Significance was determined by two-way ANOVA with Bonferroni post-hoc analysis. Significant effect of time was found for aspartate transaminase. Significant effect of hospitalization status was found for absolute lymphocyte count, hemoglobin, and albumin. There was a significant interaction between time and hospitalization status for absolute lymphocyte count with post-hoc analysis indicating significance during hospitalization. Significance (p<0.05) effect of time or hospitalization is indicated by **bold font** with significant sub-groups in post-hoc analysis indicated by \*.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | NON-HOSPITALIZED (*average, SEM)* | | HOSPITALIZED (*average, SEM)* | |
| White blood cells | BEFORE | 6.59 (0.30) | n= 49 | 6.57 (0.96) | n= 19 |
| DURING | 6.86 (0.86) | n= 15 | 5.29 (0.46) | n= 17 |
| AFTER | 7.28 (0.43) | n= 31 | 6.46 (0.73) | n= 11 |
| Absolute neutrophil count | BEFORE | 3.96 (0.23) | n= 48 | 4.29 (0.86) | n= 19 |
| DURING | 3.75 (0.51) | n= 15 | 3.63 (0.40) | n= 16 |
| AFTER | 4.47 (0.38) | n= 30 | 3.96 (0.60) | n= 10 |
| Absolute monocyte count | BEFORE | 0.62 (0.04) | n= 48 | 0.58 (0.05) | n= 19 |
| DURING | 0.59 (0.07) | n= 15 | 0.52 (0.06) | n= 16 |
| AFTER | 0.71 (0.07) | n= 30 | 0.53 (0.06) | n= 10 |
| **Absolute lymphocyte count** | **BEFORE** | **1.69 (0.12)** | **n= 48** | **1.45 (0.18)** | **n= 19** |
| **DURING** | **2.13 (0.36)\*** | **n= 15** | **0.85 (0.10)\*** | **n= 16** |
| **AFTER** | **1.92 (0.14)** | **n= 30** | **1.78 (0.32)** | **n= 10** |
| **Hemoglobin** | **BEFORE** | **13.23 (0.21)** | **n= 49** | **12.71 (0.42)** | **n= 19** |
| **DURING** | **13.05 (0.33)** | **n= 15** | **12.36 (0.46)** | **n= 17** |
| **AFTER** | **13.73 (0.23)** | **n= 31** | **12.03 (0.57)** | **n= 11** |
| Platelets | BEFORE | 232.80 (8.46) | n= 48 | 245.00 (8.83) | n= 19 |
| DURING | 220.27 (12.98) | n= 15 | 243.59 (23.23) | n= 17 |
| AFTER | 242.11 (12.66) | n= 31 | 278.00 (21.24) | n= 11 |
| Alanine transaminase | BEFORE | 21.71 (1.89) | n= 47 | 19.74 (3.16) | n= 19 |
| DURING | 25.40 (4.37) | n= 10 | 28.50 (4.92) | n= 16 |
| AFTER | 20.75 (3.02) | n= 20 | 16.25 (3.01) | n= 4 |
| **Aspartate transaminase** | **BEFORE** | **19.93 (1.16)** | **n= 47** | **16.11 (1.68)** | **n= 19** |
| **DURING** | **22.50 (2.98)** | **n= 10** | **31.25 (5.62)** | **n= 16** |
| **AFTER** | **17.95 (1.32)** | **n= 20** | **19.50 (2.40)** | **n= 4** |
| Total bilirubin | BEFORE | 0.61 (0.16) | n= 45 | 0.5 (0.10) | n= 18 |
| DURING | 0.44 (0.08) | n= 10 | 0.34 (0.05) | n= 14 |
| AFTER | 0.45 (0.05) | n= 16 | 0.40 (0.11) | n= 4 |
| Blood urea nitrogen | BEFORE | 17.27 (2.40) | n= 35 | 15.29 (1.06) | n= 17 |
| DURING | 16.25 (1.68) | n= 8 | 14.13 (1.46) | n= 15 |
| AFTER | 14.00 (1.29) | n= 12 | 12.86 (1.10) | n= 7 |
| Creatinine | BEFORE | 0.81 (0.03) | n= 35 | 0.69 (0.04) | n= 18 |
| DURING | 0.78 (0.10) | n= 8 | 0.74 (0.07) | n= 16 |
| AFTER | 0.74 (0.04) | n= 14 | 0.68 (0.06) | n= 7 |
| **Albumin** | **BEFORE** | **4.34 (0.09)** | **n= 37** | **4.39 (0.20)** | **n= 17** |
| **DURING** | **4.17 (0.10)** | **n= 9** | **3.71 (0.18)** | **n= 12** |
| **AFTER** | **4.38 (0.06)** | **n= 15** | **3.80 (0.12)** | **n= 3** |
| Vitamin D-25 | BEFORE | 37.59 (3.01) | n= 41 | 37.00 (3.48) | n= 18 |
| DURING | 52.25 (3.77) | n= 8 | 41.33 (10.40) | n= 3 |
| AFTER | 42.16 (3.20) | n= 20 | 47.57 (7.63) | n= 7 |

**Figure e-1. COVID-19 post-infection antibody testing by DMT**

COVID-19 antibody testing was performed between 1 and 203 days after presenting with suspected or confirmed COVID-19 infection. Graph demonstrates the number of antibody positive (left) and negative (right) patients. The stacked bars indicate the number within each group on high-, mid-, or low-efficacy, or none/other DMT. Two-way ANOVA did not demonstrate a significant association of DMT efficacy grouping with COVID-19 antibody formation.